文献速递肾小球疾病急性肾损伤

抗中性粒细胞胞质抗体(ANCA)动力学与ANCA肾小球肾炎肾脏存活及复发风险的关系

Association between kinetic of anti-neutrophil cytoplasmic antibody (ANCA), renal survival and relapse risk in ANCA glomerulonephritis.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

这项多中心回顾性研究纳入2000年1月1日起诊断的134例ANCA肾小球肾炎患者,随访56个月,分析ANCA阴性、复发和持续三种动力学特征及MPO/PR3特异性与肾脏预后的关系。ANCA复发/持续组无复发生存率更低(P=0.019),MPO-ANCA复发/持续组肾脏生存期最短(P=0.015),PR3-ANCA复发/持续组无复发生存期最差(P=0.013)。

要点

  • ANCA复发/持续组无复发生存率低于阴性组(P=0.019),肾脏生存有偏低趋势(P=0.053)。
  • MPO-ANCA复发/持续组肾脏生存期最短(P=0.015),PR3-ANCA复发/持续组无复发生存期最差(P=0.013)。
  • ANCA阴性是2年eGFR翻倍的独立预测因素(OR 6.79,95%CI 1.78-31.4,P=0.008)。

核心结论

  • ANCA-GN诊断后的ANCA动力学与结局相关,MPO-ANCA复发/持续提示肾脏恢复潜力较低和肾衰竭风险较高,PR3-ANCA复发/持续提示复发风险较高。
  • ANCA动力学可能有助于识别处于隐匿疾病活动的患者。

研究设计与样本

  • 多中心回顾性研究,纳入2000年1月1日起诊断的ANCA-GN患者。
  • 排除诊断时ANCA阴性及随访期间ANCA检测少于3次者,最终纳入134例。
  • 随访56个月(IQR 34-101),中位ANCA检测19次(IQR 13-25)。

主要发现

  • ANCA复发/持续组较阴性组无复发生存率更低(P=0.019),肾脏生存有偏低趋势(P=0.053)。
  • MPO-ANCA复发/持续组较其他特征组肾脏生存期最短(P=0.015)。
  • PR3-ANCA复发/持续组较其他特征组无复发生存期最差(P=0.013)。
  • ANCA阴性特征与更大的eGFR恢复相关。
  • 多因素回归中ANCA阴性是2年eGFR翻倍的独立预测因素(OR 6.79,95%CI 1.78-31.4,P=0.008)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anti-neutrophil cytoplasmic antibody (ANCA) kinetic in ANCA-associated vasculitis with glomerulonephritis (AAV-GN) has been suggested to be associated with AAV relapse. Few studies have focused on its association with renal prognosis. Thus we aimed to investigate the relationship between ANCA specificity and the evolutive profile and renal outcomes. METHODS: This multicentric retrospective study included patients diagnosed with ANCA-GN since 1 January 2000. Patients without ANCA at diagnosis and with fewer than three ANCA determinations during follow-up were excluded. We analysed estimated glomerular filtration rate (eGFR) variation, renal-free survival and relapse-free survival according to three ANCA profiles (negative, recurrent and persistent) and to ANCA specificity [myeloperoxidase (MPO) or proteinase 3 (PR3)]. RESULTS: Over a follow-up of 56 months [interquartile range (IQR) 34-101], a median of 19 (IQR 13-25) ANCA determinations were performed for the 134 included patients. Patients with a recurrent/persistent ANCA profile had a lower relapse-free survival (P = .019) and tended to have a lower renal survival (P = .053) compared with those with a negative ANCA profile. Patients with a recurrent/persistent MPO-ANCA profile had the shortest renal survival (P = .015) and those with a recurrent/persistent PR3-ANCA profile had the worst relapse-free survival (P = .013) compared with other profiles. The negative ANCA profile was associated with a greater eGFR recovery. In multivariate regression analysis, it was an independent predictor of a 2-fold increase in eGFR at 2 years [odds ratio 6.79 (95% confidence interval 1.78-31.4), P = .008]). CONCLUSION: ANCA kinetic after an ANCA-GN diagnosis is associated with outcomes. MPO-ANCA recurrence/persistence identifies patients with a lower potential of renal recovery and a higher risk of kidney failure, while PR3-ANCA recurrence/persistence identifies patients with a greater relapse risk. Thus ANCA kinetics may help identify patients with a smouldering disease.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Samoreau C, Piccoli GB, Martin C, et al. Association between kinetic of anti-neutrophil cytoplasmic antibody (ANCA), renal survival and relapse risk in ANCA glomerulonephritis. Nephrol Dial Transplant. 2023. PMID: 36043422. doi:10.1093/ndt/gfac240

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。